75 Establishing strategies to accurately differentiate radiation necrosis from recurrence and tumor progression has the potential to significantly improve the care and quality of life of patients treated aggressively for lesions of equivocal significance. 75 Notably, this could enable clinicians to halt further radiotherapy and potentially alleviate symptoms using drugs such as bevacizumab or corticosteroids. 76–78 Several publications have focused on discriminating cases of radiation necrosis from local recurrence (LR) or tumor progression in BM p
1
—
—